Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP.

Haematologica. 2019 Feb 21. pii: haematol.2018.207266. doi: 10.3324/haematol.2018.207266. [Epub ahead of print]

2.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, Heck AJ, Schuurman J, Parren PW.

PLoS Biol. 2016 Jan 6;14(1):e1002344. doi: 10.1371/journal.pbio.1002344. eCollection 2016 Jan.

3.

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW.

Mol Immunol. 2015 Oct;67(2 Pt A):117-30. doi: 10.1016/j.molimm.2015.01.028. Epub 2015 Feb 17. Review.

4.

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW.

Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.

5.

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, Parren PW.

MAbs. 2014 Mar-Apr;6(2):392-402. doi: 10.4161/mabs.27705. Epub 2014 Jan 3.

6.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub 2013 Mar 11.

7.

Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.

Strumane K, Rygiel T, van der Valk M, Collard JG.

J Cancer Res Clin Oncol. 2009 Jan;135(1):69-80. doi: 10.1007/s00432-008-0437-8. Epub 2008 Jul 1.

PMID:
18592271
8.

The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation.

Rygiel TP, Mertens AE, Strumane K, van der Kammen R, Collard JG.

J Cell Sci. 2008 Apr 15;121(Pt 8):1183-92. doi: 10.1242/jcs.017194. Epub 2008 Mar 18.

9.

The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression.

Bonnomet A, Polette M, Strumane K, Gilles C, Dalstein V, Kileztky C, Berx G, van Roy F, Birembaut P, Nawrocki-Raby B.

Oncogene. 2008 Jun 12;27(26):3692-9. doi: 10.1038/sj.onc.1211035. Epub 2008 Jan 28.

PMID:
18223680
10.

Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.

Strumane K, Song JY, Baas I, Collard JG.

Leuk Res. 2008 Jan;32(1):113-20. Epub 2007 May 22.

PMID:
17521720
11.

E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion.

Strumane K, Bonnomet A, Stove C, Vandenbroucke R, Nawrocki-Raby B, Bruyneel E, Mareel M, Birembaut P, Berx G, van Roy F.

Cancer Res. 2006 Oct 15;66(20):10007-15.

12.

The Rac activator Tiam1 and Ras-induced oncogenesis.

Strumane K, Rygiel TP, Collard JG.

Methods Enzymol. 2006;407:269-81.

PMID:
16757331
13.

Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons.

De Preter K, Pattyn F, Berx G, Strumane K, Menten B, Van Roy F, De Paepe A, Speleman F, Vandesompele J.

BMC Genomics. 2004 Feb 3;5(1):11.

14.

Cadherins in cancer.

Strumane K, Berx G, Van Roy F.

Handb Exp Pharmacol. 2004;(165):69-103. doi: 10.1007/978-3-540-68170-0_4.

PMID:
20455091
15.

Quantitative cell dispersion analysis: new test to measure tumor cell aggressiveness.

Nawrocki Raby B, Polette M, Gilles C, Clavel C, Strumane K, Matos M, Zahm JM, Van Roy F, Bonnet N, Birembaut P.

Int J Cancer. 2001 Sep 1;93(5):644-52.

16.

An efficient and reliable multiplex PCR-SSCP mutation analysis test applied to the human E-cadherin gene.

Berx G, Nollet F, Strumane K, van Roy F.

Hum Mutat. 1997;9(6):567-74.

PMID:
9195232
17.

E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.

Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C.

Oncogene. 1996 Nov 7;13(9):1919-25.

PMID:
8934538

Supplemental Content

Loading ...
Support Center